hex-5-enal oxime | 57606-81-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: hex-5-enal oxime
• 英文别名: (NE)-N-hex-5-enylidenehydroxylamine
• CAS: 57606-81-2
• 化学式: C₆H₁₁NO
• 分子量: 113.159
• InChiKey: ISRXXTMGMKQMOO-VOTSOKGWSA-N

物化性质

• 沸点：
  63-64 °C(Press: 2 Torr)
• 密度：
  0.87±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  hex-5-enal oxime 以93%的产率得到
  参考文献：
  名称：

  HOUSE H. O.; LEE L. F., J. ORG. CHEM. , 1976, 41, NO 5, 863-869

  摘要：

  DOI：
• 作为产物：
  描述：

  5-己烯醛 、 Hydroxyazanium;chloride 以87%的产率得到
  参考文献：
  名称：

  HOUSE H. O.; LEE L. F., J. ORG. CHEM. , 1976, 41, NO 5, 863-869

  摘要：

  DOI：

文献信息

• FUSED AMINODIHYDROTHIAZINE DERIVATIVES
  申请人：SUZUKI Yuichi

  公开号：US20090209755A1

  公开（公告）日：2009-08-20

  A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C 6-14 aryl group or the like, L is —NR e CO— or the like (wherein R e is a hydrogen atom or the like), Ring B is a C 6-14 aryl group or the like, X is a C 1-3 alkylene group or the like, Y is a single bond or the like, Z is a C 1-3 alkylene group or the like, R 1 and R 2 are each independently a hydrogen atom or the like, and R 3 , R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  一个由以下通用公式表示的化合物：或其药用可接受的盐或其溶剂化物，其中环A是C6-14芳基或类似物，L是—NReCO—或类似物（其中Re是氢原子或类似物），环B是C6-14芳基或类似物，X是C1-3烷基烯基或类似物，Y是单键或类似物，Z是C1-3烷基烯基或类似物，R1和R2各自独立地是氢原子或类似物，而R3、R4、R5和R6各自独立地是氢原子、卤原子或类似物，具有Aβ产生抑制作用或BACE1抑制作用，并且可用作由Aβ引起的以阿尔茨海默型痴呆为特征的神经退行性疾病的预防或治疗剂。
• [EN] A NOVEL PROCESS FOR THE PREPARATION OF CHIRAL CYCLOPENTANONE INTERMEDIATES<br/>[FR] NOUVEAU PROCÉDÉ DE PRÉPARATION D'INTERMÉDIAIRES DE CYCLOPENTANONE CHIRALE
  申请人：PHARMATHEN SA

  公开号：WO2015051903A1

  公开（公告）日：2015-04-16

  The present invention relates to a process for the preparation of chiral cyclopentanone derivatives, using easily accessible starting materials.

  本发明涉及一种制备手性环戊酮衍生物的方法，使用易于获得的起始原料。
• Tandem nucleophilic substitution - 1,3 dipolar cycloaddition reactions of oximes with epoxides and dipolarophiles
  作者：Ronald Grigg、Jasothara Markandu

  DOI：10.1016/s0040-4039(01)80601-8

  日期：1989.1

  Regiospecific nucleophilic substitution reactions involving attack of the nitrogen atom of oximes on epoxides are used to generate nitrones which are then trapped in 1,3-dipolar cycloaddition reactions. These tandem processes are shown to be flexible and to have wide synthetic scope for the construction of complex molecular frameworks.

  涉及肟的氮原子对环氧化物的攻击的区域特异性亲核取代反应用于产生硝酮，然后将其捕获在1，3-偶极环加成反应中。这些串联过程显示出灵活性，并具有广泛的合成范围，可用于构建复杂的分子框架。
• Medicinal Composition Containing Diabeted Remedy
  申请人：Izumi Masanori

  公开号：US20080039367A1

  公开（公告）日：2008-02-14

  A pharmaceutical composition effective for the prophylaxis and treatment of diabetes is provided. This pharmaceutical composition comprises the combination of an α-amylase inhibitor selected from a compound represented by the following general formula (I): [wherein A represents, for example, a cyclic group, etc. R 1 and R 2 represent an alkyl group, hydroxymethyl group, etc., and n represents 1 or 2], or a pharmacologically acceptable salt or ester thereof, and at least one type of drug selected from an insulin sensitizer, an insulin secretagogue, a biguanide drug, an insulin preparation and a DPP-IV inhibitor.

  提供一种用于预防和治疗糖尿病的药物组合物。该药物组合物包括以下通用式（I）所表示的化合物中选择的α-淀粉酶抑制剂：[其中A代表环状基团等，R1和R2代表烷基、羟甲基基团等，n代表1或2]，或其药理学上可接受的盐或酯，以及选择自胰岛素增敏剂、胰岛素分泌促进剂、双胍类药物、胰岛素制剂和DPP-IV抑制剂中的至少一种药物。
• Oligosaccharide Derivative
  申请人：Honda Takeshi

  公开号：US20080194495A1

  公开（公告）日：2008-08-14

  Compounds having the formula (I): wherein A represents a group such as a cyclic group, R 1 and R 2 represent groups such as alkyl groups or hydroxymethyl groups, and n represents 1 or 2, or pharmacologically acceptable salts thereof or pharmacologically acceptable esters thereof have superior activity and stability, and are useful for the treatment and/or prevention of diabetes mellitus, or the like.

  具有式(I)的化合物：其中A表示环状基团，R1和R2表示烷基或羟甲基等基团，n表示1或2，或其药学上可接受的盐或酯，在活性和稳定性方面具有优越性，可用于治疗和/或预防糖尿病等疾病。